Three and a half years after the pandemic outbreak, now that WHO has formally declared
that the emergency is over, COVID-19 is still a significant global issue. Here, we focus on …

ABSTRACT COVID-19, a respiratory infectious disease, occurs due to Severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). Millions of individuals around the world …

This ongoing, open-label, phase 2/3 trial compared the safety and immunogenicity of the
Omicron BA. 4/BA. 5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan …

Background Long-term effectiveness of COVID-19 mRNA boosters in populations with
different previous infection histories and clinical vulnerability profiles is inadequately …

Although the coronavirus disease (COVID-19) emergency status is easing, the COVID-19
pandemic continues to affect healthcare systems globally. It is crucial to have a reliable and …

The bivalent (original and Omicron BA. 4/BA. 5) mRNA-1273 COVID-19 vaccine was
authorized to offer broader protection against COVID-19. We conducted a matched cohort …

COVID-19 vaccines are safe and reduce COVID-19 mortality. The World Health
Organization (WHO) recommends that countries prioritize populations at increased risk, eg …

We estimated the effectiveness of booster doses of monovalent mRNA COVID-19 vaccines
against Omicron-associated severe outcomes among adults in Ontario, Canada. We used a …

The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants that evade immunity elicited by vaccination has placed an imperative on the …

A mucosal route of vaccination could prevent severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) replication at the site of infection and limit transmission. We …